Formosa Pharmaceuticals is a clinical stage biotech with focus in ophthalmology, oncology, and anti-infectives.
● APP13007 (Clobetasol Propionate Ophthalmic Nanosuspension, 0.05%), a novel formulation for the treatment of inflammation and pain after ocular surgery, is under preparation for NDA submission to the US FDA.
● Our proprietary APNT formulation platform, from which APP13007 is developed, is available for regional licensing, CDMO services, or co-development.
● Formosa Pharma is also developing a biosimilar of Kadcyla®, which is also available for licensing or co-development.